Detail akcie Forte Bioscienc Rg online

Business Summary: Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Forte Biosciences Inc revenues was not reported. Net loss increased 96% to $69.4M. Higher net loss reflects therapeutic genes segment loss increase of 93% to $70.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$12.17 to -$4.71.